GR38032F, a 5HT3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting
Authors:
- 1 June 1989
- journal article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 23 (6) , 389-391
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy.Journal of Clinical Oncology, 1988
- Identification and distribution of 5-HT3 receptors in rat brain using radioligand bindingNature, 1987
- Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research.Journal of Clinical Oncology, 1987
- Optimising antiemesis in cancer chemotherapy: efficacy of continuous versus intermittent infusion of high dose metoclopramide in emesis induced by cisplatin.BMJ, 1986
- Inhibition of cisplatin‐induced vomiting by selective 5‐hydroxytryptamine M‐receptor antagonismBritish Journal of Pharmacology, 1986
- DOSE-RESPONSE RELATIONSHIPS OF THE OBJECTIVE AND SUBJECTIVE ANTIEMETIC EFFECTS AND OF DIFFERENT SIDE-EFFECTS OF METOCLOPRAMIDE AGAINST CISPLATIN INDUCED EMESIS1986
- Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patientsCancer, 1985
- Peripheral 5-hydroxytryptamine receptors and their classificationNeuropharmacology, 1984
- High-dose metoclopramide in cancer chemotherapy-induced nausea and vomiting.1982
- Antiemetic Efficacy of High-Dose Metoclopramide: Randomized Trials with Placebo and Prochlorperazine in Patients with Chemotherapy-Induced Nausea and VomitingNew England Journal of Medicine, 1981